Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xarelto for Thromboprophylaxis After Arthroplasty
NCT05449327Completed
- Sponsor
- Ditmanson Medical Foundation Chiayi Christian Hospital
- Start
- Feb 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Ditmanson Medical Foundation Chiayi Christian Hospital. Primary endpoints: Deep Vein Thrombosis at 3 months and Pulmonary Embolism at 3 months. Started Feb 2023; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05449327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05449327.